Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

by · The Cerbat Gem

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

A number of other equities analysts have also commented on the company. Oppenheimer lowered their price objective on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 12th. JMP Securities reiterated a “market outperform” rating and issued a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st.

Check Out Our Latest Research Report on CLLS

Cellectis Price Performance

Cellectis stock opened at $2.21 on Thursday. The stock’s fifty day moving average price is $2.21 and its two-hundred day moving average price is $2.41. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The firm has a market cap of $122.84 million, a PE ratio of -1.71 and a beta of 3.09.

Cellectis (NASDAQ:CLLS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. As a group, research analysts expect that Cellectis will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Several hedge funds and other institutional investors have recently modified their holdings of CLLS. Principal Financial Group Inc. increased its stake in shares of Cellectis by 6.2% in the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock valued at $1,125,000 after purchasing an additional 24,906 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after acquiring an additional 10,605 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Cellectis during the 2nd quarter valued at $29,000. Finally, Long Focus Capital Management LLC boosted its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Further Reading